{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:34:40Z","timestamp":1773099280980,"version":"3.50.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jad-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jad.2014.12.015","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T09:01:40Z","timestamp":1418374900000},"page":"467-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Taking the fuel out of the fire: Evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders"],"prefix":"10.1016","volume":"174","author":[{"given":"Ziada","family":"Ayorech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek K.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Giaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2014.12.015_bib92","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Amer Psychiatric Pub Incorporated., Washington, DC.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.jad.2014.12.015_bib1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain \u03c9-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial","volume":"67","author":"Amminger","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0165-0327(02)00322-1","article-title":"Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania","volume":"73","author":"Angst","year":"2003","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1586\/ern.11.42","article-title":"Therapeutic use of omega-3 fatty acids in bipolar disorder","volume":"11","author":"Balanz\u00e1-Mart\u00ednez","year":"2011","journal-title":"Expert Rev. Neurother"},{"key":"10.1016\/j.jad.2014.12.015_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/360481","article-title":"Cytokines in bipolar disorder: paving the way for neuroprogression","author":"Barbosa","year":"2014","journal-title":"Neural Plast."},{"key":"10.1016\/j.jad.2014.12.015_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00127-014-0887-z","volume":"49","author":"Baumeister","year":"2014","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.jad.2014.12.015_bib93","doi-asserted-by":"crossref","unstructured":"Baumeister, D., Tojo, L., Tracy, D.K., Legal highs: staying on top of the flood of novel psychoactive substances, Ther. Adv. Psychopharmacol., http:\/\/dx.doi.org\/10.1177\/2045125314559539, in press.","DOI":"10.1177\/2045125314559539"},{"key":"10.1016\/j.jad.2014.12.015_bib6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","article-title":"N-acetyl cysteine for depressive symptoms in bipolar disorder \u2013 a double-blind randomized placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jad.2011.06.005","article-title":"The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial","volume":"135","author":"Berk","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1741-7015-11-74","article-title":"Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness","volume":"11","author":"Berk","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.jad.2014.12.015_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1741-7015-10-91","article-title":"Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial","volume":"10","author":"Berk","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.jad.2014.12.015_bib10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.neubiorev.2010.10.001","article-title":"Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors","volume":"35","author":"Berk","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2014.12.015_bib97","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1399-5618.2007.00536.x","article-title":"The Bipolar Depression Rating Scale (BDRS): its development, validation and utility","volume":"9","author":"Berk","year":"2007","journal-title":"Bipolar disorders"},{"key":"10.1016\/j.jad.2014.12.015_bib11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.mehy.2013.02.001","article-title":"Is there a role for curcumin in the treatment of bipolar disorder?","volume":"80","author":"Brietzke","year":"2013","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.jad.2014.12.015_bib94","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/2045125312471963","article-title":"Lithium: the pharmacodynamic actions of the amazing ion","volume":"3","author":"Brown","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.12.015_bib12","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.4088\/JCP.v66n1219b","article-title":"Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder","volume":"66","author":"Chiu","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1399-5618.2008.00625.x","article-title":"Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second\u2010generation antipsychotics","volume":"10","author":"Correll","year":"2008","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/NMD.0000000000000136","article-title":"The reliability of self-assessment of affective state in different phases of bipolar disorder","volume":"202","author":"da Silva","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jad.2014.12.015_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jad.2014.12.015_bib16","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.pnpbp.2007.02.018","article-title":"Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder","volume":"31","author":"Dickerson","year":"2007","journal-title":"Progress Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.psyneuen.2012.08.005","article-title":"Reduced regulatory T cells are associated with higher levels of Th1\/TH17 cytokines and activated MAPK in type 1 bipolar disorder","volume":"38","author":"do Prado","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jad.2014.12.015_bib18","first-page":"321","article-title":"Quality of life enjoyment and satisfaction questionnaire","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2014.12.015_bib19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2011.11071009","article-title":"Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care","volume":"169","author":"Fardet","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/bjp.188.1.46","article-title":"Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study","volume":"188","author":"Frangou","year":"2006","journal-title":"Br. J. Psychiatry: J. Ment. Sci."},{"key":"10.1016\/j.jad.2014.12.015_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0269881106067787","article-title":"Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder","volume":"21","author":"Frangou","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.12.015_bib23","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","article-title":"Treatment of bipolar disorder","volume":"381","author":"Geddes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2014.12.015_bib24","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4088\/JCP.08r04505","article-title":"Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature","volume":"70","author":"Goldstein","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study","author":"Grant","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the longterm treatment of bipolar disorder","volume":"14","author":"Grunze","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib27","doi-asserted-by":"crossref","unstructured":"Guy W., (Ed.), 1976, Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology-Revised, The ECDEU Assessment Manual for Psychopharmacology-Revised vol. 76, pp. 218\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"10.1016\/j.jad.2014.12.015_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0033-3182(95)71666-8","article-title":"Global assessment of functioning: a modified scale","volume":"36","author":"Hall","year":"1995","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2014.12.015_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11920-013-0387-y","article-title":"Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications","volume":"15","author":"Hamdani","year":"2013","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2014.12.015_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.psychres.2013.04.006","article-title":"Everyday functional ability across different phases of bipolar disorder","volume":"210","author":"Henry","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2014.12.015_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2005.11.016","article-title":"Affective lability and affect intensity as core dimensions of bipolar disorders during euthymic period","volume":"159","author":"Henry","year":"2008","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2014.12.015_bib33","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1176\/appi.ajp.161.10.1922","article-title":"Omega-3 fatty acid treatment and T2 whole brain relaxation times in bipolar disorder","volume":"161","author":"Hirashima","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1096\/fj.01-0707fje","article-title":"Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-\u03b1 suppression","volume":"16","author":"Joussen","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.jad.2014.12.015_bib35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1586\/ern.09.31","article-title":"Clinical implications of a staging model for bipolar disorders","volume":"9","author":"Kapczinski","year":"2009","journal-title":"Exp. Rev. Neurother."},{"key":"10.1016\/j.jad.2014.12.015_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2014.12.015_bib37","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.biopsych.2006.03.056","article-title":"Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder","volume":"60","author":"Keck","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib38","first-page":"2528","article-title":"The increasing medical burden in bipolar disorder","volume":"293","author":"Kupfer","year":"2005","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive\u2013compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2014.12.015_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2012.05.031","article-title":"Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients","volume":"72","author":"Laje","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.neubiorev.2007.05.008","article-title":"Convergent Functional Genomics of bipolar disorder: from animal model pharmacogenomics to human genetics and biomarkers","volume":"31","author":"Le-Niculescu","year":"2007","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2014.12.015_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2011.12.049","article-title":"Can bipolar disorder be viewed as a multi-system inflammatory disease?","volume":"141","author":"Leboyer","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib99","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2045125311420752","article-title":"Bipolar depression: clinically missed, pharmacologically mismanaged","volume":"1","author":"Lloyd","year":"2011","journal-title":"Ther. Advan. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.12.015_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11011-008-9118-1","article-title":"The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression","volume":"24","author":"Maes","year":"2009","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.jad.2014.12.015_bib45","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0004867413481631","article-title":"A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania","volume":"47","author":"Magalhaes","year":"2013","journal-title":"Aust. N.Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S1516-44462011000400011","article-title":"N-acetylcysteine for major depressive episodes in bipolar disorder","volume":"33","author":"Magalh\u00e3es","year":"2011","journal-title":"Rev. Bras. de Psiquiatr."},{"key":"10.1016\/j.jad.2014.12.015_bib47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/07315724.2009.10719785","article-title":"EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials","volume":"28","author":"Martins","year":"2009","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.jad.2014.12.015_bib48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/j.1440-1614.2006.01860.x","article-title":"Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions","volume":"40","author":"McGorry","year":"2006","journal-title":"Aust. N.Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaac.2013.11.013","article-title":"Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review","volume":"53","author":"Mitchell","year":"2014","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biopsych.2013.01.007","article-title":"Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies","volume":"74","author":"Modabbernia","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.jad.2014.12.015_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005169.pub2","article-title":"Omega-3 fatty acids for bipolar disorder","volume":"2","author":"Montgomery","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2014.12.015_bib53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-3223(00)00252-3","article-title":"Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2\u2032s neurotrophic effects?","volume":"48","author":"Moore","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"M\u00fcller","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2014.12.015_bib56","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial anti-psychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"Mu\u00a8ller","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib57","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jpsychires.2013.05.018","article-title":"Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis","volume":"47","author":"Munkholm","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2014.12.015_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jad.2012.06.010","article-title":"Cytokines in bipolar disorder: a systematic review and meta-analysis","volume":"144","author":"Munkholm","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/JCP.0b013e318266854c","article-title":"Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial","volume":"32","author":"Murphy","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.12.015_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Nery","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.12.015_bib61","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2014.12.015_bib62","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4088\/JCP.v66n0608","article-title":"Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study","volume":"66","author":"Osher","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib63","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1038\/tp.2012.125","article-title":"Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder","volume":"2","author":"Perron","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib64","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.4088\/JCP.v64n1108","article-title":"Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs","volume":"64","author":"Phelan","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib65","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/schbul\/sbm060","article-title":"Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V","volume":"33","author":"Phillips","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2014.12.015_bib66","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00004714-199010000-00009","article-title":"The clinical significance of lithium-nonsteroidal: anti-inflammatory drug interactions","volume":"10","author":"Ragheb","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.12.015_bib67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","article-title":"Cytokines sing the blues: inflammation and the pathogenesis of depression","volume":"27","author":"Raison","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jad.2014.12.015_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib69","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.biopsych.2005.02.024","article-title":"Celecoxib augmentation of continuously ill patients with schizophrenia","volume":"57","author":"Rapaport","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archpsyc.1983.01790030053006","article-title":"Indomethacin but not aspirin increases plasma lithium ion levels","volume":"40","author":"Reimann","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2014.12.015_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.09m05324gre","article-title":"L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study","volume":"72","author":"Ritsner","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2014.01.013","article-title":"Inflamed moods: a review of the interactions between inflammation and mood disorders","volume":"53C","author":"Rosenblat","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib74","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bdi.12108","article-title":"Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study","volume":"15","author":"Saroukhani","year":"2013","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2014.12.015_bib76","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jad.2012.04.005","article-title":"The prognostic role of perceived criticism, medication adherence and family knowledge in bipolar disorders","volume":"142","author":"Scott","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib77","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1192\/bjp.bp.112.110858","article-title":"Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value","volume":"202","author":"Scott","year":"2013","journal-title":"Br. J. Psychiatry: J. Ment. Sci."},{"key":"10.1016\/j.jad.2014.12.015_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/0269881113485143","article-title":"Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples","author":"Serretti","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.12.015_bib79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.phrs.2003.05.003","article-title":"Adverse drug reactions: role of pharmacogenomics","volume":"49","author":"Severino","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jad.2014.12.015_bib80","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.4088\/JCP.12m08049","article-title":"Recovery from multiple episodes of bipolar I depression","volume":"74","author":"Solomon","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.plefa.2009.10.007","article-title":"Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder","volume":"82","author":"Stolk","year":"2010","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.jad.2014.12.015_bib82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.56.5.407","article-title":"Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial","volume":"56","author":"Stoll","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib84","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1681\/ASN.V103666","article-title":"Lithium intoxication","volume":"10","author":"Timmer","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jad.2014.12.015_bib85","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0006-3223(98)00159-0","article-title":"Activation of indices of cell-mediated immunity in bipolar mania","volume":"45","author":"Tsai","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0165-0327(00)00252-4","article-title":"Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania","volume":"64","author":"Tsai","year":"2001","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.atherosclerosis.2013.02.028","article-title":"Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis","volume":"228","author":"van Diepen","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jad.2014.12.015_bib88","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1992"},{"key":"10.1016\/j.jad.2014.12.015_bib89","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.immuni.2013.05.015","article-title":"Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation","volume":"38","author":"Yan","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jad.2014.12.015_bib90","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jad.2011.06.016","article-title":"Annual cost of managing bipolar disorder to the UK healthcare system","volume":"133","author":"Young","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.12.015_bib96","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jad.2014.12.015_bib91","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.biopsych.2007.06.008","article-title":"N-acetylcysteine reduces extinction responding and induces enduring reductions in cue-and heroin-induced drug-seeking","volume":"63","author":"Zhou","year":"2008","journal-title":"Biol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032714008015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032714008015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T09:33:20Z","timestamp":1650792800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032714008015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":96,"alternative-id":["S0165032714008015"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2014.12.015","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taking the fuel out of the fire: Evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2014.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}